CaPCure

CaPCure was a biotechnology company primarily focused on the development of novel immunotherapies and personalized vaccines for the treatment of prostate cancer. The company's core technology centered on a dendritic cell-based vaccine platform, which utilized mRNA to program a patient's own immune system to recognize and attack prostate cancer cells. Founded as a spin-off from academic research at the University of Florida, CaPCure aimed to translate laboratory breakthroughs in urological oncology into clinical applications. While the entity was active in the early 2010s, it has since become dormant, though its foundational research contributed to the broader field of cancer immunotherapy.